Streetbeat News

Price Targets

STE

JMP Securities analyst David Turkaly has reiterated a 'Market Outperform' rating on Steris (NYSE:STE) and maintained a price target of $265.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:25 pm

VCSA

JMP Securities analyst Nicholas Jones has maintained a Market Outperform rating on Vacasa (NASDAQ:VCSA), but lowered the price target from $30 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:22 pm

FLL

JMP Securities analyst Jordan Bender maintains a Market Outperform rating on Full House Resorts (NASDAQ:FLL) but lowers the price target from $9 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:19 pm

CART

JMP Securities analyst Andrew Boone maintains a Market Outperform rating on Maplebear (NASDAQ:CART) and raises the price target from $33 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:15 pm

ANGI

Benchmark analyst Daniel Kurnos has maintained a 'Buy' rating on Angi (NASDAQ:ANGI) but lowered the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:10 pm

UAA

Piper Sandler analyst Abbie Zvejnieks has maintained a Neutral rating on Under Armour (NYSE:UAA) and lowered the price target from $10 to $8.5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:05 pm

RVNC

Piper Sandler analyst David Amsellem maintains an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $44 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:04 pm

RVNC

Piper Sandler analyst David Amsellem maintains an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $44 to $42.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:03 pm

RAMP

Benchmark analyst Mark Zgutowicz maintains a Buy rating on LiveRamp Holdings (NYSE:RAMP) and raises the price target from $37 to $44.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:00 pm

LFMD

HC Wainwright & Co. has maintained its Buy rating for LifeMD (NASDAQ:LFMD) and increased its price target from $9.00 to $10.00. LifeMD shares are currently trading up 3.07% at $7.38 per share. A move to $10.00 would represent a 35.5% increase from the current share price.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 5:00 pm